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BACKGROUND: Optimal cellular immunotherapy for cancer should ideally harness both the innate and adaptive arms of the immune
response. Lymphokine-activated killer cells (LAKs) can trigger early innate killing of tumour targets, whereas long-term adaptive-
specific tumour control requires priming of CD8þ cytotoxic lymphocytes (CTLs) following acquisition of tumour-associated antigens
(TAAs) by antigen-presenting cells such as dendritic cells (DCs). As DCs stimulate both innate and adaptive effectors, combination
cell therapy using LAKs and DCs has the potential to maximise anti-tumour immune priming.
METHODS: Reciprocal activation between human clinical grade LAKs and DCs on co-culture, and its immune consequences, was
monitored by cell phenotype, cytokine release and priming of both innate and adaptive cytotoxicity against melanoma targets.
RESULTS: Co-culture of DCs and LAKs led to phenotypic activation of natural killer (NK) cells within the LAK population, which was
associated with increased production of inflammatory cytokines and enhanced innate cytotoxicity against tumour cell targets. The
LAKs reciprocally matured DCs, and the combination of LAKs and DCs, on addition of melanoma cells, supported priming of specific
anti-tumour CTLs better than DCs alone.
CONCLUSION: Clinical-grade LAKs/DCs represents a practical, effective combination cell immunotherapy for stimulation of both innate
and adaptive anti-tumour immunity in cancer patients.
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Induction of efficient immunity against tumours requires a
coordinated interplay between the innate and adaptive arms of
the immune response. Dendritic cells (DCs) are components of the
early innate immune system and can also prime specific, adaptive
responses. In particular, cross-presentation of tumour-associated
antigens (TAAs) via MHC-I molecules on the surface of DCs can
expand specific cytotoxic lymphocytes (CTLs), potentially leading
to a long-term anti-tumour memory response (Banchereau and
Steinman, 1998).
Natural killer (NK) cells are early innate immune effectors that
can exert direct nonspecific cytotoxicity against tumour cells
(Srivastava et al, 2008). In addition to their role as initiators of
antigen-specific responses, DCs also support the tumouricidal
activity of NK cells (Fernandez et al, 1999), and the extent of cross-
talk between DCs and NK cells, leading to reciprocal activation of
both cell subsets, has become increasingly recognised (Kalinski
et al, 2005; Semino et al, 2005). Significantly, NK/DC interactions
can promote the generation of tumour-specific T-cell responses,
whereby NK cells function as nominal ‘helper’ cells to support
adaptive anti-tumour immunity (Reschner et al, 2008).
Lymphokine-activated killer cells (LAKs) are a heterogeneous
population of cells consisting primarily of NK, NKT and T cells,
which are generated in vitro by culture of peripheral blood
mononuclear cells (PBMCs) in IL-2 (Grimm et al, 1982). The
predominant effector cells within LAKs are NK cells, which are
mechanistically equivalent to peripheral blood NK cells, but are
more cytotoxic against tumour cells, including otherwise NK-
resistant targets (Grimm et al, 1982). Moreover, LAKs are more
readily cultured in large numbers for administration to patients
than purified NK cells. LAKs have previously been shown to
localise to tumour sites in both mouse (Kjaergaard et al, 2000) and
human systems (Keilholz et al, 1994), and therefore have the
potential to access and lyse tumours in patients following systemic
administration in vivo. Although there was considerable clinical
interest in LAKs for cancer therapy towards the end of the last
century, their application for patients has not progressed, in part
due to concerns about the toxicity associated with IL-2, which had
to be co-administered to maintain LAK activation in vivo
(Rosenberg, 1988).
As with NK cells, there is evidence that DCs can reciprocally
activate LAKs in vitro (Valteau-Couanet et al, 2002; Capobianco
et al, 2006). A recent murine study has also shown that co-
injection of LAKs and DCs into tumours led to regression
associated with protection against secondary rechallenge (Capo-
bianco et al, 2008). These data suggest that combination LAK/DC
therapy holds promise as a treatment for cancer, based on the
hypothesis that DC-activated LAKs will effectively kill tumour
targets to liberate TAAs for uptake by DCs within an inflammatory
tumour microenvironment. The TAA-loaded mature DCs will
then migrate to secondary lymphoid tissue and present TAAs
to resident T cells for priming of an additional adaptive
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antigen-specific response. Moreover, activation of LAKs by co-
administered DCs may remove the need for IL-2 and hence reduce
the toxicity associated with LAK therapy in the past.
This preclinical study investigated the interaction between
clinically relevant LAKs and DCs, their ability to reciprocally
activate each other, and the potential of the LAK/DC combination
to prime both innate and adaptive immune responses against
melanoma in human in vitro priming assays. We show that DCs
are effectively matured by LAKs, while maintaining their
phagocytic function for effective uptake of potential TAAs. In
parallel, LAK cytotoxicity is enhanced by co-culture with DCs, as is
secretion of inflammatory IFNg and TNFa. Furthermore, the
addition of LAKs to tumour cell co-cultures with DCs increases
specific CTL priming. Hence, LAKs/DCs have potential as a
combination cell immunotherapy for priming of both innate and
adaptive anti-tumour immunity.
MATERIALS AND METHODS
Dendritic cell culture
Buffy coats obtained from healthy donors or whole blood taken
from melanoma patients (with written, informed consent in
accordance with local institutional ethics review and approval)
were used to isolate PBMCs by Ficoll-Hypaque density centrifuga-
tion. Monocytes were isolated by MACS CD14þ selection
(Miltenyi, Bergisch Gladbach, Germany) according to manufac-
turer’s instructions and were consistently found to be495% pure.
The CD14þ cells were additionally assessed for NK, NKT and
T-cell contamination, and were found to be low (average 2.6%,
1.5% and 4.8%, respectively). Immature DCs were generated from
CD14þ monocytes in serum-free DC media (CellGro DC media;
Cell Genix, Freiberg, Germany) supplemented with 800 IUml1
GMCSF (Peprotech, London, UK) and 500 IUml1 IL-4 (R&D
Systems, Abingdon, UK) for 5 days. OK432 (Chugai Pharmaceu-
tical Co., Tokyo, Japan) was used at 1000 IUml1 to generate
mature DCs (West et al, 2009).
Lymphokine-activated killer cell generation
CD14 PBMC, isolated following CD14 selection (as above), were
routinely found to be negative for CD14+ cell contamination
(o5%). LAKs were generated from CD14 PBMC in LAK media
(CellGro SCGM media; Cell Genix) supplemented with 5% (v/v)
pooled human serum (Sera Labs, Haywards Heath, UK) and
1000 IUml1 IL-2 (Peprotech) for 5–7 days in non-coated tissue
culture flasks (Berdeja et al, 2007).
Tumour cell lines
K562, Daudi and Skov3 cells were maintained in RPMI-1640 (Sigma,
Gillingham, UK) supplemented with 10% (v/v) FCS (BioSera,
Ringmer, UK) and 1% (v/v) L-glutamine (Sigma). Melanoma cell
lines (Mel888, Mel624, MeWo and SKMel-28) were maintained in
DMEM (Sigma) supplemented with 10% (v/v) FCS and 1% (v/v)
L-glutamine. All cell lines were routinely tested for mycoplasma and
found to be free of infection.
Lymphokine-activated killer cell/DC co-cultures
Freshly harvested LAKs and DCs were co-cultured together at a
ratio of 10 : 1, in mixed culture media (50 : 50 LAK:DC media
without cytokines) at a density of 2 106ml1 LAKs for 48 h.
Tumour cell lines were included at a 1 : 1 ratio with DCs at the
onset of culture, as required.
Flow cytometry
DCs and LAKs were analysed using the following antibodies with
appropriate isotype controls. CD11cþ DCs: anti-human CD14-PE,
CD40-PE, CD83-PE, CD86-PE, HLA-DR-PE, MICA/B-PE, CD155-
PE, MHC class 1-PE, ICAM-1-PE (BD Biosciences, Oxford, UK),
CCR7-PE, ULBP1-PE, ULBP2-PE, CD112-PE, CCR1-PE, CCR5-PE,
CXCR1-PE and CXCR2-PE (R&D Systems). LAK (CD3þCD56,
CD3-CD56þ and CD3þCD56þ ): anti-human CD3-PerCP, CD56-
FITC, CD8-FITC, CD16-FITC, CD69-FITC, NKG2D-PE, CCR7-PE,
DNAM-1-PE, NKp30-PE, NKp44-PE, LFA-1(CD18)-PE, CD40 L
(CD154)-PE (BD Biosciences), CD56-PE (Serotec, Oxford, UK)
and NKp46-PE (Miltenyi). Flow cytometry was performed using a
BD FACSCalibur and analysed using BD CellQuest Pro software.
ELISA
Supernatants from 48 h LAK/DC co-cultures were assessed for
levels of IL-4, IL-5, IL-6, IL-8, IL-10, IL-12 (p40 and p70), TNFa
and IFNg by ELISA using antibody matched pairs (all from BD
Biosciences except TNFa, which was obtained from Invitrogen,
Paisley, UK) according to the manufacturer’s instructions.
Degranulation assay
LAK degranulation as a response to target recognition was
measured using CD107 surface expression as previously described
(Prestwich et al, 2008). Briefly, LAKs were co-cultured±DCs for
48 h before co-incubation with tumour targets (1 : 1 ratio
LAK:tumour cell) for 4 h, before CD107 staining. LAKs were
additionally stained for CD3 and CD56. Analysis was performed by
flow cytometry.
Cytotoxicity assay
DC and LAK cytotoxicity was measured using a standard 4 h 51Cr
release assay as previously described (Errington et al, 2006).
Briefly, 51Cr-labelled cell targets were incubated with LAKs, DCs or
combination LAKs/DCs (pre-cultured together for 48 h) at varying
effector to target (E : T) ratios. To examine the perforin
dependence of LAK cytotoxicity, E : T co-cultures were set
up±2mM EGTA (Sigma). Percent lysis was calculated using the
following formula: % lysis¼ 100 (sample c.p.m.spontaneous
c.p.m.)/(maximum c.p.m.spontaneous c.p.m.).
Dendritic cell phagocytosis assay
DCs were pulsed with FITC-dextran (Sigma)±LAKs (1 : 10 ratio)
for 60min at 371C (or 41C control). DCs were harvested at 15min
intervals, stained with CD11c-PE and then analysed by flow
cytometry for FITC-dextran uptake.
Generation of tumour-specific CTL
DCs were cultured with Mel888 cells for 48 h, either in the presence
or absence of LAKs, at 1 : 3 : 10 ratio, respectively, to permit
loading of antigen on to the DCs, as previously described
(Errington et al, 2006). These tumour-loaded DCs were then
mixed with autologous PBMCs at a 1 : 30 ratio to generate tumour-
specific CTLs. CTLs were re-stimulated 7 days later with a second
population of tumour-loaded DCs±LAKs. At 14 days, CTLs were
harvested and used immediately in cytotoxicity studies against
Mel888 and an irrelevant target (Skov3).
Statistical analyses
Statistical analysis was performed using paired t-tests where
Po0.05 denotes a significant result.
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RESULTS
Lymphokine-activated killer cells are a heterogeneous
population consisting of NK, NKT and T cells
This preclinical study used Good Manufacturing Practice-
compliant components to generate both LAKs and DCs, to ensure
translational relevance for application in human clinical trials.
Initial phenotypic analysis of LAKs alone revealed a mixed
population consisting predominantly of CD3-CD56þ cells
(NK-LAK), CD3þCD56þ cells (NKT-LAK) and CD3þCD56
cells (T-LAK). The relative proportions of the three sub-popula-
tions significantly changed during LAK generation by culture of
PBMCs in IL-2 (Figure 1A and B). The NK cells increased from
10.1±1.2% in PBMCs to 24.2±4.1% in LAK, NKT cells from
3.9±1.9% to 11.7±3.5%, whereas the T-cell population reduced
from 57.7±3.6% to 45.3±2.7%.
Investigations into changes in expression of cell surface
molecules during LAK cell generation were performed on these
three predominant cell types (Figure 1C and D). Cells of interest
were initially identified by their CD3/CD56 expression, as
designated in Figure 1A, before analysis of specific activation
markers. A significant increase in expression of both NK-specific
activation markers (NKp30, NKp44 and NKp46) and general
activation markers (CD69, NKG2D and DNAM-1) in IL-2-activated
NK-LAK, in comparison with resting NK cells in PBMCs, was
observed. In agreement with other studies, NKp30 and NKp46
were detected at low levels on resting NK cells and increased on
activation, whereas NKp44 was found only on activated cells
(Bryceson et al, 2006). The NK-LAK CD16 levels were high at the
onset of culture and remained so, whereas CCR7 expression was
consistently low. CD40L staining was low or absent on NK-, NKT-
and T-LAK (data not shown). The NKT-LAK increased expression
of CD69, NKG2D and DNAM-1 compared with NKT in PBMCs,
although NK-specific markers remained low or absent (Figure 1C).
As expected, the T-cell fraction of PBMCs or LAKs exhibited very
low positivity for all NK-specific receptors; however, other
activation markers and CCR7 increased following LAK generation
(Figure 1C). The adhesion molecule LFA-1 was found on all
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Figure 1 Phenotype of clinical grade LAKs and DCs. Phenotype analysis was performed on CD14 PBMCs before and after culture for 5 days in IL-2 to
generate LAKs. (A) Relative populations of NK (CD3 CD56þ ), NKT (CD3þCD56þ ) and T cells (CD3þCD56) are shown as representative plots
from one donor (of n¼ 10); (B) mean % of total cells (PBMCs grey bars, LAKs black bars)±s.e.m (of n¼ 10 donors; *Po0.05). Expression of activation
markers on LAKs are shown as representative plots from one donor (of n¼ 5): (C) % positive expression and (D) mean fluorescence intensity of LFA-1
(*Po0.05). DCs were generated by culture of CD14þ PBMCs with GMCSF and IL-4 for 5 days. (E) Phenotype analysis is shown as representative FACS
plots from one donor (of n¼ 5; DCs: black; isotype controls: grey).
Combination LAK/DC therapy
EJ West et al
789
British Journal of Cancer (2011) 105(6), 787 – 795& 2011 Cancer Research UK
T
ra
n
sl
a
ti
o
n
a
l
T
h
e
ra
p
e
u
ti
c
s
subsets, and its expression uniformly increased following culture
in IL-2 (Figure 1D).
Clinical grade DCs exhibit an immature phenotype
CD11c-positive clinical DCs were subjected to phenotype analysis
of cell surface markers and found to be positive for CD40, CD86,
MHC-I and class II (HLA-DR) (Figure 1E), but negative for CD83,
CCR7 and CD14 (data not shown): a phenotype indicative of
immature DCs (West et al, 2009). Other markers, including ligands
for activating NK receptors (MICA/B, ULBP1 and 2, CD112), were
not expressed (data not shown). ICAM-1 was highly expressed
(Figure 1E), correlating with high expression of its receptor,
LFA-1, on LAK (Figure 1D). Staining for chemokine/cytokine
receptors (CCR1, CCR5 and CXCR1) was also positive (Figure 1E).
Dendritic cells activate LAKs
Experiments were performed to explore potential reciprocal
activation between clinical grade LAKs and DCs. Expression of
NK-LAK cell surface markers is shown in Figure 2. There was
significant upregulation of CD16, NKp30, NKp44 and NKp46 on
NK-LAK when co-cultured with DCs for 48 h. Stimulation of the
early activation marker CD69 was also apparent, as was upregula-
tion of DNAM-1. However, levels of both NKG2D (already highly
expressed) and CCR7 (consistently low) on NK-LAK were not
significantly altered by DCs. A similar trend of DC-induced
activation was also seen on NKT-LAK and T-LAK (for non-NK
specific markers only), although this did not reach statistical
significance (Supplementary Figure 1). The LFA-1 on NK-LAK was
further enhanced by DCs (data not shown).
Lymphokine-activated killer cells induce DC maturation
We next addressed the effects of LAKs on DCs. Although previous
work has shown that DCs can be lysed by autologous NK/LAK cells
(Parajuli et al, 1999), there was no significant killing of DCs by
LAK in our clinical grade system (Supplementary Figure 2).
Analogous to DC-induced LAK activation, LAKs effectively
matured autologous DCs on co-culture (Figure 3B). Maturation
was apparent from significant upregulation of CD83, CCR7 and
MHC-I expression. Enhancement of CD40 and CD86 was also seen,
although this did not reach statistical significance over all six donors.
An increase in the levels of the cytokine/chemokine receptors CCR1,
CCR5, CCR7, CXCR1 and CXCR2 on DCs in the presence of LAKs
was also seen, as was upregulation of the activating NK receptor
ligands, MICA/B, ULBP1 and ULBP2 (ligands for NKG2D), as well as
CD112 and CD155 (ligands for DNAM-1). In addition, we observed
some increase in the already high levels of ICAM-1, although this was
donor dependent (data not shown).
To assess this combination therapy within a clinical setting,
we performed additional experiments with blood taken from
melanoma patients with metastatic disease (stage IV), not on
active current treatment. The data demonstrate that LAKs and DCs
can be successfully generated from patient PBMCs, and that
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Figure 2 DCs mediated activation of NK-LAK. LAKs and DCs were co-cultured at 10 : 1 ratio for 48 h before NK-LAK (CD3-CD56þ ) phenotype analysis.
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they similarly cross-activate each other, as demonstrated by
enhanced expression of cell surface activation/maturation mole-
cules (Supplementary Figure 3).
We also tested the phagocytic capacity of DCs co-cultured with
LAKs, to determine whether LAK-matured DCs retained the ability
to take up TAAs potentially released by LAK-lysed tumour cells.
For this, uptake of FITC-dextran by DCs was measured±LAK.
Figure 3C demonstrates that, even on co-culture with maturation-
inducing LAKs, DCs remained functional for uptake of exogenous
material, an essential step for DC-mediated priming of an adaptive
anti-tumour CTL response.
Reciprocally activated LAKs/DCs secrete inflammatory
cytokines
The cytokine profile of LAK/DC co-culture supernatants was
measured by ELISA (Figure 4). Increases in secretion of the
inflammatory cytokines IL-6, IL-8 and IFNg were observed,
together with a nonsignificant trend for IL-12p40 and TNFa, in
LAK/DC co-cultures compared with LAKs and/or DCs alone.
However, IL-12p70 remained undetectable (data not shown),
whereas anti-inflammatory IL-10 production by DCs showed a
trend to reduction on co-culture with LAKs, although this was
donor dependent and not statistically significant across multiple
donors.
Melanoma cells do not inhibit LAK/DC reciprocal activation
Melanoma cells are known to suppress the function of immune
cells, including DCs and NK cells (Real et al, 2001). As we are
proposing LAKs/DCs as a cytotoxic and immunogenic combina-
tion cell therapy on interaction with tumour cell targets, we next
investigated whether the presence of melanoma cells would have a
deleterious effect on the cross-activation between LAKs and DCs
described above. The LAKs/DCs were therefore co-cultured with
the human melanoma cell lines Mel888 or MeWo, which were
found to have no significant effect on reciprocal LAK/DC
activation, as demonstrated both by cell phenotype data and
cytokine production (Supplementary Figures 4 and 5).
Dendritic cells enhance perforin-dependent LAK
cytotoxicity against tumour targets
To test whether DC-mediated activation of LAKs enhanced their
killing of tumour targets, cytotoxic activity was measured using
standard 4 h 51Cr-release assays. The LAK, DC and LAK/DC killing
of four melanoma cell lines (alongside NK-sensitive K562 and NK-
resistant Daudi targets) is shown in Figure 5A. As expected, DCs
alone did not kill tumour targets. LAKs exhibited significant
cytotoxicity against both K562 and Daudi cells, and were also
variably active against the different melanoma lines. Pre-activation
of LAKs by DCs resulted in consistent and significantly enhanced
killing of the majority of tumour targets (B20% over that observed
for LAKs alone at all E:T ratios). Substantial killing of melanoma
targets was also seen using patient-derived LAKs, which was
enhanced by pre-incubation with DCs (Supplementary Figure 3).
As 51Cr-release assays measure target killing by LAKs as an
entire population, to distinguish the relative cytolytic activity of
the cell populations within LAKs, degranulation assays were used.
The degree of CD107 expression was measured on the surface of
LAKs during exposure to Daudi and Mel888, following
pre-culture±DCs for 48 h (Figure 5B and C). The results show
the NK-LAK fraction degranulated most following co-culture with
targets. Although there was measurable background degranulation
of both NK-LAK and NKT-LAK in the absence of targets, only
CD107 on NK-LAK increased against Daudi and Mel888 following
previous activation of LAKs by DCs. T-LAKs did not degranulate
under any conditions tested.
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To determine the mechanism of cytotoxicity utilised by LAKs,
we repeated Cr51-release assays in the presence of EGTA
(Figure 5D). The reduction in LAK (and LAK/DC) cytotoxicity in
the presence of EGTA, which chelates the calcium required for
perforin release, is consistent with our previous data demonstrat-
ing that DC-stimulated NK cell cytotoxicity is a perforin-
dependent process (Errington et al, 2008).
Lymphokine-activated killer cells enhance the ability of
DCs to prime an antigen-specific CTL response
Data thus far has demonstrated an effective interaction between
DCs and LAKs, resulting in reciprocal activation and enhancement
of nonspecific innate immune killing of melanoma targets,
predominantly by NK-LAK. As DCs form a direct link between
innate and adaptive immune responses, we investigated the
potential of LAKs/DCs to support adaptive priming of specific
CTLs subsequent to early innate tumour killing. Tumour-specific
CTLs were generated against Mel888 targets using DCs alone or
LAKs/DCs in an MHC class I-dependent in vitro human CTLs
priming assay (Errington et al, 2006). As anticipated, a positive
control comprising DCs matured with the bacterial adjuvant
OK432 (West et al, 2009) induced an adaptive Mel888-specific
response in autologous T cells, whereas CTL priming by immature
DCs alone was ineffective (Figure 6). However, the combination
of LAKs and immature DCs resulted in potent specific CTL
priming, with even higher levels of killing than those elicited by
OK432-matured DCs. Hence, the ability of co-cultured LAKs to kill
targets and/or mature DCs improves adaptive anti-tumour
immune priming.
DISCUSSION
The aim of this preclinical study was to investigate the innate and
adaptive immune anti-tumour potential of a deliverable, clinical
grade human LAK/DC combination cell therapy for the treatment
of cancer, in particular melanoma. LAKs are a clinically applicable
heterogeneous population of innate cytotoxic cells consisting
predominantly of NK, NKT and T cells. On ex vivo culture of
human PBMCs in IL-2, we observed an expansion in NK and NKT
cells, with a corresponding reduction in T cells (Figure 1B). This is
consistent with previously published data (Valteau-Couanet et al,
2002; Capobianco et al, 2006), suggesting that NK cells are the
main effectors within LAKs. The NK-LAKs were activated
compared with ‘resting’ NK cells in PBMCs, as indicated by
expression of both general surface activation markers (CD69,
NKG2D and DNAM-1) and the NK-specific natural cytotoxicity
receptors (NCRs) NKp30, NKp44 and NKp46; NKT-LAKs and T-
LAKs were also activated by IL-2 (Figure 1C). The DCs used in this
study exhibited a typical immature phenotype with low CD83 and
CCR7 expression, high MHC-I and II and positive staining for
CCR1, CCR5 and CXCR1 (Figure 1E). Notably, ligands for NK
activating receptors were initially present at low levels on DCs
(Figure 3B), whereas the adhesion molecule ICAM-1 (the ligand for
LFA-1 as expressed on LAKs, Figure 1D) was consistently
expressed at high levels.
Mouse and human LAK/NK cells are known to activate DCs
in vitro (Valteau-Couanet et al, 2002; Capobianco et al, 2006) and
vice versa (Kalinski et al, 2005; Yano et al, 2006), and we found
similar reciprocal activation in our clinical grade LAK/DC co-
cultures. The DC-mediated LAK activation was evident from
further increased expression of NCRs on NK-LAK, and CD69,
DNAM-1 and NKG2D on NK-, NKT- and T-LAK (Figure 2). In
parallel, LAKs induced maturation of DCs (Figure 3B). Multiple
mechanisms are thought to underlie NK/DC cross-talk, including
contact-dependent interactions involving CD40/CD40L (Yano et al,
2006), NKp30 (Vitale et al, 2005) and DNAM-1 (Chan et al, 2010)
in cooperation with NKp30 (Balsamo et al, 2009). Although the
detailed interactions between LAKs/DCs are unknown, our data
clearly show that following co-culture: (i) NCR on NK-LAK were
upregulated (Figure 2) and (ii) known ligands for NK cell
activating receptors NKG2D (MICA/B, ULBP1 and ULBP2) and
DNAM-1 (CD112 and CD155) were increased on DCs (Figure 3).
LFA-1 present on LAKs, alongside ICAM-1 expression on DCs, was
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Figure 4 Cytokine secretion by LAK/DC co-cultures. Levels of cytokines were measured in supernatants from 48 h cultures of LAKs, DCs or LAKs/DCs
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also further enhanced during co-culture. LFA-1 and ICAM-1 are
involved in cell–cell interaction during an inflammatory response,
and LFA-1 is particularly important during NK interaction with
antigen-presenting cells and T cells (Borg et al, 2004). Taken
together, these findings are consistent with LAK/DC co-culture
enhancing the effector functions of NK-LAK via direct cellular
cross-talk.
In addition to cell–cell contact, cytokines are also proposed to
have a role in NK or LAK/DC cross-activation, and may also direct
the nature of the innate and adaptive immune responses they elicit
in vivo. Enhanced levels of IL-6 (Figure 4) detected in LAK/DC co-
cultures can stimulate NK and LAK cell proliferation and
cytotoxicity (Iho and Shau, 1994) and neutralise regulatory T-cell
suppression to facilitate T-cell activation by DCs (Schmidt et al,
2004; Detournay et al, 2005). Immunosuppressive IL-10 produc-
tion by DCs was variably inhibited in the presence of LAKs
(Figure 4), a finding consistent with previous data (Schmidt et al,
2004). Significant secretion of IL-8 by LAK/DC co-cultures
(Figure 4) was detected alongside upregulated CXCR1 and 2
expression on DCs (Figure 3B). As a major function of IL-8 is to
induce chemotaxis of cells expressing its receptors (CXCR1 and
CXCR2) to sites of inflammation in the initial phases of an innate
response (Mukaida, 2000), this data supports the potential for
LAK/DC-derived IL-8 to sustain additional endogenous effector
cell trafficking into targeted tumour sites in vivo. Increased IFNg
and TNFa were also observed in LAK/DC co-cultures (Figure 4).
The NK-secreted IFNg is postulated to be essential for DC
maturation (Kalinski et al, 2005; Capobianco et al, 2006), whereas
both IFNg and TNFa contribute to induction of stable type-1
polarised DC (so-called ‘DC1’) (Kalinski et al, 2005). Hence, if
LAKs mature co-administered and/or endogenous DCs in vivo in
the context of IFNg/TNFa, these DCs have the potential to migrate
to lymph nodes via CCR7-mediated chemotaxis (Figure 3B) to
enhance Th1-adaptive priming.
Although LAKs matured DCs (Figure 3B), these DCs could still
take up FITC-dextran (Figure 3C), illustrating their competence for
acquiring exogenous material from their immediate environment,
an important function for cross-priming of TAAs potentially
released by dying tumour cells in vivo. Moreover, the presence of
melanoma cells did not inhibit cross-activation between LAKs and
DCs in vitro in terms of phenotype and cytokine production
(Supplementary Figures 4 and 5), suggesting that LAKs/DCs may
be able to reverse immunosuppression to induce an inflammatory
microenvironment within tumours, appropriate for induction of
therapeutic immune priming.
Consistent with previous reports that DCs can stimulate NK
cytotoxicity against tumour targets (Valteau-Couanet et al, 2002;
Capobianco et al, 2006), we found that DCs enhanced innate tumour
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cell killing by LAKs (Figure 5A). The NK cells were the predominant
population within DC-activated LAKs, which degranulated against
targets (Figure 5B and C). Moreover, NK-LAK lysed archetypal NK-
resistant Daudi cells, as well as classical NK-susceptible targets (K562;
Friberg et al, 1996), further demonstrating their potency over that of
isolated NK cells. Consistent with our previous data on DC-activated
NK cells (Errington et al, 2008), this killing was perforin-mediated
(Figure 5D). Hence, the phenotypic activation of LAKs by DCs
(Figure 2) led to enhanced innate cytotoxicity.
In addition to early direct tumour eradication by LAKs/DCs as a
combination cell therapy, we wished to address whether the
presence of LAKs could enhance the anti-tumour CTL priming
efficacy of DCs, thereby forming a link between the innate and
adaptive potential of cellular immunotherapy. DCs can modulate
the innate responses of NK cells (Kalinski et al, 2005), NKT cells
(Takahashi et al, 2002) and gdT cells (Dieli et al, 2004) to
potentially connect with an adaptive anti-tumour memory immune
response (Capobianco et al, 2008). Moreover, DC/NK cell
interactions can circumvent the need for CD4þ T cell help during
induction of CTLs (Adam et al, 2005), further increasing the appeal
of adding LAKs to DCs for enhanced adaptive priming. Figure 6
shows, in an established human in vitro system for assessing
generation of specific anti-melanoma CTLs, that LAKs consistently
improved DC-mediated CTL priming to a level greater than that of
OK432-matured DCs. Although it is currently unclear whether the
benefit of LAKs in this context is due to their tumour-killing
capability leading to enhanced antigen release, their ability to
mature DCs, or a combination of the two, this data suggests that a
LAK/DC combination has the potential to enhance adaptive as well
as innate anti-tumour effects in patients in vivo.
In summary, this study shows that clinical grade LAKs and DCs
can be readily generated in vitro in large numbers, both from
healthy donors and patients with advanced melanoma, using
established methodologies which have already been applied
separately and safely in the clinic. As DCs maintain and activate
LAKs, the combination could be applied in vivo without addition
of toxic, systemic IL-2. Functionally, innate direct cytotoxicity
of LAKs is improved by DCs, and adaptive CTL priming by DCs
is enhanced by the presence of LAKs. This data supports
the development of LAKs/DCs as a practical, clinically deliverable
combination cellular immunotherapy for the treatment of
cancer, and a clinical protocol in melanoma is currently in
development.
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